Cannara Biotech Inc.
LOVFF
$1.18
-$0.05-3.67%
OTC PK
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.83% | 35.70% | 26.34% | 27.49% | 23.90% |
| Total Other Revenue | 265.93% | -- | -- | -- | 155.62% |
| Total Revenue | 22.81% | 35.70% | 26.34% | 27.49% | 25.52% |
| Cost of Revenue | 27.95% | 11.27% | -11.63% | 31.40% | 45.21% |
| Gross Profit | 16.71% | 80.35% | 169.61% | 22.12% | 8.12% |
| SG&A Expenses | 24.72% | 14.19% | -4.91% | 30.68% | 40.55% |
| Depreciation & Amortization | 55.09% | -9.57% | 16.66% | -31.90% | 280.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.16% | 10.57% | -10.17% | 28.94% | 44.62% |
| Operating Income | 6.13% | 349.19% | 372.44% | 20.65% | -16.71% |
| Income Before Tax | 19.31% | 177.46% | 228.82% | 42.89% | -20.16% |
| Income Tax Expenses | 162.70% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.51% | 98.41% | 190.28% | 8.60% | 20.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.51% | 98.41% | 190.28% | 8.60% | 20.91% |
| EBIT | 6.13% | 349.19% | 372.44% | 20.65% | -16.71% |
| EBITDA | 11.58% | 164.79% | 1,268.20% | 12.41% | -8.31% |
| EPS Basic | -43.47% | 95.15% | 189.82% | 8.77% | 24.53% |
| Normalized Basic EPS | 16.28% | 28,300.00% | 227.93% | 42.99% | -21.82% |
| EPS Diluted | -50.00% | 93.20% | 185.91% | 27.40% | 20.00% |
| Normalized Diluted EPS | 15.38% | 27,900.00% | 225.70% | 42.45% | -23.18% |
| Average Basic Shares Outstanding | 1.58% | 1.57% | 0.60% | -0.22% | -2.83% |
| Average Diluted Shares Outstanding | 2.03% | 1.18% | 2.48% | 0.62% | -1.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |